The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC)

公平癌症护理护理点技术创新与转化中心 (CITEC)

基本信息

  • 批准号:
    10715740
  • 负责人:
  • 金额:
    $ 130万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-13 至 2028-07-31
  • 项目状态:
    未结题

项目摘要

Abstract: Cancer is the first or second leading cause of premature death in 134 of 183 countries, and it is estimated that global incidence of cancer will increase by 50% from 2018 to 2040. The number of cases is projected to double in countries with low Human Development Index; these countries have the least resources and infrastructure to adequately care for cancer patients. Disparities exist within countries; in the US, racial and ethnic minorities and other medically underserved populations share a disproportionate burden for many types of cancer. Most cancers can be cured if detected early and treated effectively. To reduce premature death, the World Health Organization recommends implementing early cancer detection and prevention programs at the primary care level. Yet, existing tests for early cancer detection are too complex and/or expensive to implement in primary care settings, particularly in medically underserved areas. We will establish the Center for Innovation and Translation of Point-of-Care Technologies for Equitable Cancer Care (CITEC) to identify high- priority clinical needs for POC cancer technologies; to accelerate development of effective, affordable technologies to meet these needs; to evaluate and improve the clinical and public health impact of POC technologies in diverse settings; and to train developers and users to create and disseminate more equitable POC technologies. CITEC will prioritize development of POC tests to detect cancers that arise in epithelial surfaces. Initially, we will focus on sites accessible for early detection because this is where POC technologies can have the most immediate impact. Targeted organ sites include the uterine cervix, gastro-intestinal tract (esophagus, stomach, colon, rectum, anus), and oral cavity; cancers in these sites account for 26% of global cases and 29% of global cancer deaths. CITEC builds on the highly productive 15-year collaboration between Rice University, The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, and The University of Texas Health Science Center at Houston to develop and translate novel POC technologies to improve cancer care in both low- and high-resource settings. Joining with collaborators in Brazil at The University of Sao Paulo and Barretos Cancer Hospital and partners in Mozambique at The Universidade Eduardo Mondlane and Ministry of Health, we will create a collaborative center to support technology development and engage and support a global community of investigators dedicated to creating and scaling POC technologies for equitable cancer screening and diagnosis to facilitate early treatment. CITEC will support development of POC technologies to promote high priority topics of NIH cancer research, including precision approaches to prevention, screening and early detection, reducing disparities in cancer outcomes, and building a diverse workforce able to translate POC technologies from research and development to equitable implementation. CITEC will have a major impact on equitable prevention, diagnosis and early treatment of cancer in the US and worldwide, and will work with the POCTRN network to build a strong team of global partners to strengthen and sustain POC technology development.
抽象的: 在 183 个国家中的 134 个国家中,癌症是导致过早死亡的第一或第二大原因,据估计,全球 从 2018 年到 2040 年,癌症发病率将增加 50%。在癌症国家,癌症病例数预计将增加一倍 人类发展指数低;这些国家拥有最少的资源和基础设施来充分护理癌症 患者。国家内部存在差异;在美国,少数族裔和其他医疗服务不足的人 人口对多种类型的癌症承担着不成比例的负担。如果及早发现,大多数癌症都可以治愈 得到有效治疗。为了减少过早死亡,世界卫生组织建议实施早期癌症治疗 初级保健层面的检测和预防计划。然而,现有的早期癌症检测测试过于复杂 和/或在初级保健机构中实施成本高昂,特别是在医疗服务不足的地区。我们将建立 公平癌症护理即时护理技术创新与转化中心 (CITEC) 旨在确定高 POC 癌症技术的优先临床需求;加速开发有效、负担得起的技术 满足这些需求;评估和改善 POC 技术在不同环境中的临床和公共卫生影响; 培训开发者和用户创建和传播更公平的 POC 技术。 CITEC将优先考虑 开发 POC 测试来检测上皮表面出现的癌症。最初,我们将重点关注可访问的网站 及早发现,因为这是 POC 技术可以产生最直接影响的地方。目标器官部位包括 子宫颈、胃肠道(食道、胃、结肠、直肠、肛门)和口腔;这些部位的癌症 占全球癌症病例的 26% 和全球癌症死亡人数的 29%。 CITEC 建立在 15 年高产的基础上 莱斯大学、德克萨斯大学 MD 安德森癌症中心、贝勒医学院、 与德克萨斯大学休斯敦健康科学中心合作开发和转化新型 POC 技术,以改善 资源匮乏和资源丰富环境中的癌症护理。与巴西圣保罗大学的合作者一起 巴雷托斯癌症医院以及莫桑比克爱德华多·蒙德拉内大学和卫生部的合作伙伴,我们 将创建一个协作中心来支持技术开发并参与和支持全球社区 研究人员致力于创建和扩展 POC 技术,以实现公平的癌症筛查和诊断,以促进 及早治疗。 CITEC 将支持 POC 技术的开发,以促进 NIH 癌症的高度优先主题 研究,包括预防、筛查和早期检测的精确方法,减少癌症的差异 成果,并建立一支多元化的员工队伍,能够将 POC 技术从研发转化为 公平执行。 CITEC 将对公平预防、诊断和早期治疗产生重大影响 并将与 POCTRN 网络合作,建立一支强大的全球合作伙伴团队, 加强和维持POC技术的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sharmila Anandasabapathy其他文献

Sharmila Anandasabapathy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sharmila Anandasabapathy', 18)}}的其他基金

Low Cost Tethered Capsule Endoscope with High-Resolution Digital Chromoscopy for Barrett's Screening
用于巴雷特氏筛查的低成本系留胶囊内窥镜,具有高分辨率数字色谱法
  • 批准号:
    10295900
  • 财政年份:
    2021
  • 资助金额:
    $ 130万
  • 项目类别:
Low Cost Tethered Capsule Endoscope with High-Resolution Digital Chromoscopy for Barrett's Screening
用于巴雷特氏筛查的低成本系留胶囊内窥镜,具有高分辨率数字色谱法
  • 批准号:
    10438892
  • 财政年份:
    2021
  • 资助金额:
    $ 130万
  • 项目类别:
Low Cost Tethered Capsule Endoscope with High-Resolution Digital Chromoscopy for Barrett's Screening
用于巴雷特氏筛查的低成本系留胶囊内窥镜,具有高分辨率数字色谱法
  • 批准号:
    10672889
  • 财政年份:
    2021
  • 资助金额:
    $ 130万
  • 项目类别:
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL)Diagnosis for People Living with HIV
高分辨率显微内窥镜 (HRME) 在 HIV 感染者的高级上皮内病变 (HSIL) 诊断中的有效性
  • 批准号:
    10523516
  • 财政年份:
    2018
  • 资助金额:
    $ 130万
  • 项目类别:
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV
高分辨率显微内窥镜 (HRME) 在 HIV 感染者高度上皮内病变 (HSIL) 诊断中的有效性
  • 批准号:
    10058207
  • 财政年份:
    2018
  • 资助金额:
    $ 130万
  • 项目类别:
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL)Diagnosis for People Living with HIV
高分辨率显微内窥镜 (HRME) 在 HIV 感染者的高级上皮内病变 (HSIL) 诊断中的有效性
  • 批准号:
    10311046
  • 财政年份:
    2018
  • 资助金额:
    $ 130万
  • 项目类别:
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
高分辨率显微内窥镜治疗食管肿瘤
  • 批准号:
    8928571
  • 财政年份:
    2014
  • 资助金额:
    $ 130万
  • 项目类别:
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
高分辨率显微内窥镜治疗食管肿瘤
  • 批准号:
    8759964
  • 财政年份:
    2014
  • 资助金额:
    $ 130万
  • 项目类别:
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
高分辨率显微内窥镜治疗食管肿瘤
  • 批准号:
    9325455
  • 财政年份:
    2014
  • 资助金额:
    $ 130万
  • 项目类别:
Automated, Augmented Reality High Resolution Microendoscopy for the Management of Esophageal Neoplasia
用于治疗食管肿瘤的自动化增强现实高分辨率显微内窥镜检查
  • 批准号:
    9236004
  • 财政年份:
    2014
  • 资助金额:
    $ 130万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 130万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 130万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了